Toremifene has quickly established itself as a very common and popular anti-estrogen.
This is largely due to promising clinical trials that have demonstrated its effectiveness.
Specifically, it has demonstrated several advantages over its close sister compound, Nolvadex, although some disadvantages have also been shown.
All of this was covered in detail in the characteristics sub-category of the introduction to Toremifene in this article.
Toremifene is a very new compound in the medical establishment.
It is an even more recent compound among bodybuilders and athletes in the world of anabolic steroids and performance and physique enhancement.
Therefore, the reader must understand that the clinical details regarding Toremifene (Fareston) are almost exclusively focused on female breast cancer patients, for whom this compound is currently used.
When determining details such as the proper Toremifene dosage, it is crucial to understand that the response experienced by a breast cancer patient is very different from that which a bodybuilder or athlete would experience at any given Toremifene dose.
Furthermore, this difference in response is not only limited to Toremifene dosage but also extends to its general effects.
Toremifene is a new drug, only officially approved for use in 1997.
As of this writing, its use in clinical and medical settings spans less than 30 years.
Even then, it wasn’t until the early to mid-2000s that it began to see use within the anabolic steroid community, when bodybuilders and athletes started to take notice.
In comparison, Nolvadex has been extensively used and researched in the medical field for over 50 years, and its applications and outcomes are well-established.
While Toremifene has been shown not to exhibit certain characteristics known of Nolvadex (such as hepatic carcinogenic effects from long-term use or a drastic reduction in IGF-1 levels), this does not for a moment mean that Toremifene is free of these effects.
For all intents and purposes, Toremifene is a sibling drug very closely related to Nolvadex, and it is highly probable that these effects simply have not yet been documented with Toremifene use.
In general, the dosage for Toremifene must be much higher than that of its closest analogue, Nolvadex.
Of course, Toremifene dosages will vary depending on the intended purpose.
For bodybuilders and athletes who use anabolic steroids, Toremifene use and dosages are dictated by two primary applications.
The first is to mitigate, block, or prevent gynecomastia, and the second is to restore endogenous testosterone production during Post Cycle Therapy (PCT) following the conclusion of an anabolic steroid cycle.
One of the advantages of Toremifene’s lower potency and effectiveness compared to Nolvadex is that it allows for a wider margin for dosage adjustments.
For example, the Toremifene dosage required to combat gynecomastia is far less than the dose needed for the restoration of HPTA function.
This will be covered in greater detail in this section of the profile.
Before delving into the specifics of use and dosage, the reader must be made aware of the following critical point:
The use of any SERM or anti-estrogen should only be undertaken when absolutely necessary.
Once the requirement for its use (e.g., gynecomastia or insufficient androgen production) has been resolved, its use should be discontinued immediately.
Medical Toremifene Dosage
Toremifene (Fareston) is medically and clinically prescribed for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive (or estrogen receptor-unknown) tumor growth.
For this purpose, the medical dosage of Toremifene is 60mg per day.
Most clinical studies conducted on breast cancer patients (as well as animal studies) have administered medical Toremifene doses in the range of 30 – 60mg per day.
In any case, most prescription Toremifene products are formulated in 60mg tablets.
Toremifene Dosage for Anabolic Steroid Users
Due to the nature of the compound, it is impossible to categorize Toremifene dosages into the typical three tiers (Beginner, Intermediate, and Advanced).
These three tiers are: Beginner, Intermediate, and Advanced.
This is a breakdown typically seen in most profiles concerning other anabolic steroids and performance-enhancing drugs.
Specifically, Toremifene is not typically used for the sole (or direct) purpose of physique or performance enhancement, but is instead known as an ancillary compound.
As an ancillary compound, Toremifene is utilized by anabolic steroid users to mitigate various undesirable side effects resulting from the excessive production of Estrogen during an anabolic steroid cycle.
In a sense, Toremifene could be said to enhance performance to some degree due to its endogenous testosterone-boosting effects via HPTA stimulation.
However, taking Toremifene for this purpose is highly unlikely to result in any significant changes to performance or physique.
In this context, Toremifene dosing protocols are best reserved for use during Post Cycle Therapy (PCT) with the goal of restoring HPTA and endogenous hormonal function.
For the mitigation of gynecomastia (prevention, treatment, reduction, etc.): For the prevention of gynecomastia during the use of aromatizing anabolic steroids, a Toremifene dosage of 30 – 60mg per day is required.
If gynecomastia has already begun to develop or is already present, a more robust Toremifene dosage of 120mg per day is advisable until the symptoms of gynecomastia subside.
In cases where gynecomastia has already developed or is actively progressing, it is recommended to run Toremifene alongside an Aromatase Inhibitor (AI) for maximum effectiveness.
One important point of note is that while Nolvadex has been demonstrated to negatively impact IGF-1 levels during use, this effect has not yet been demonstrated with Toremifene in clinical studies.
For this reason, the chronic daily use of Nolvadex during a cycle is not recommended.
This is because it can cause a sharp reduction in levels of IGF-1, a very important anabolic hormone, thereby impacting potential gains during a cycle.
However, it must be remembered that Toremifene is a sibling compound nearly identical to Nolvadex, and it is highly likely that it exhibits the same activity in the body, which simply has not yet been discovered in clinical studies.
While Toremifene might have far less of an impact on IGF-1 levels than Nolvadex, it is possible that increased dosages of Toremifene could exhibit the same effect.
Furthermore, Toremifene is not recommended for administration beyond the minimum necessary amount during a cycle, as it increases SHBG levels, thereby reducing total free testosterone in the body [1].
Toremifene Dosage for Females
Female anabolic steroid users do not need to be concerned with the development and growth of breast tissue (gynecomastia) and therefore have no requirement to use Toremifene.
The only notable application for Toremifene use in females is for the treatment of breast cancer patients, as mentioned in the Medical Toremifene Dosage section above.
Toremifene Dosage for Increased Endogenous Testosterone Secretion and PCT (Post Cycle Therapy)
The beneficial effects of Toremifene dosages on the male HPTA and endogenous testosterone production have been demonstrated in clinical studies.
As explained in the introduction of this profile, this is a result of its antagonistic action on the hypothalamus, where Toremifene binds to Estrogen receptors located there.
As a result, the hypothalamus is ‘tricked’ into believing there is a severe lack of Estrogen in the bloodstream, and it responds by signaling the pituitary gland to increase its production of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).
These two hormones then signal the Leydig cells in the testes to begin producing Testosterone, which in turn leads to increased aromatization into Estrogen, serving to restore the Estrogen levels that the hypothalamus was ‘tricked’ into perceiving as low.
The net result is an increase in Testosterone production and the restoration of HPTA function.
However, the Toremifene dosages required for this purpose are much greater than those needed for the mitigation or blockage of gynecomastia.
Studies have shown that Toremifene administered at 60mg daily resulted in a 42% increase in testosterone levels in test subjects [2].
While this is a significant increase, it is far lower than that of a standard 20mg daily dose of Nolvadex, which increased testosterone levels by 71% in the same study.
Therefore, it has been determined that Toremifene is not as potent as Nolvadex for this purpose, and that Toremifene dosages intended to more effectively increase testosterone production should be in the range of 120mg per day.
This dosage can be maintained for the duration of a 4 – 6 week PCT period, though some anabolic steroid users elect to taper the dosage (e.g., 120mg/day for the first week of PCT, followed by 100mg/day for the second week, and 60mg/day for the remaining 3 – 4 weeks).
Furthermore, for a more effective and comprehensive PCT protocol, the use of Toremifene alongside HCG and an Aromatase Inhibitor is highly recommended (please see the Post Cycle Therapy article for more detailed information).
Proper Administration and Timing of Toremifene
There are no special considerations regarding the administration and timing of Toremifene.
Toremifene can be administered before, during, or after meals.
It can be taken in the morning, or at night before bed.
With a half-life of 5 days, Toremifene is long-acting enough to maintain stable blood plasma levels over a 24-hour period (and beyond) without any need to split up doses throughout the day.
Expectations and Results from Toremifene Dosages
Toremifene is used to prevent, mitigate, or block the onset of gynecomastia.
For this purpose, it is best utilized either for prevention or to immediately combat gynecomastia as it begins to develop.
It is also useful for stimulating natural endogenous testosterone production following the cessation of an anabolic steroid cycle, especially when HPTA function has been suppressed or shut down from the use of exogenous androgens.
To this end, Toremifene can be utilized for hormonal recovery.
Toremifene References
[1] Effects of toremifene on endocrine regulation in breast cancer patients. Számel I, Hindi I, Vincze B, Eckhardt S, Kangas L, Hajba A. Eur J Cancer. 1994;30A(2):154-8.
[2] Effects of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. Tsourdi E, Kourtis A, Farmakiotis D, Katsikis I, Salmas M, Panidis D. Fertil Steril. 2009 Apr;91(4 Suppl):1427-30. doi: 10.1016/j.fertnstert.2008.06.002. Epub 2008 Aug 9.
